Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:ENTANASDAQ:EPRXOTCMKTS:IGXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.42+12.7%$1.14$0.87▼$6.78$141.99M0.76860,155 shs952,236 shsENTAEnanta Pharmaceuticals$5.87+0.9%$5.39$4.09▼$17.24$125.48M0.81284,623 shs44,679 shsEPRXEupraxia Pharmaceuticals$3.87+0.3%$3.58$2.20▼$4.48$138.74MN/A12,968 shs28,292 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+12.70%+13.60%+22.41%-14.46%-72.32%ENTAEnanta Pharmaceuticals+0.86%+1.38%+4.26%-25.51%-50.80%EPRXEupraxia Pharmaceuticals+0.26%+1.57%-4.21%-5.15%+37.72%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.1655 of 5 stars3.11.00.04.52.01.70.0ENTAEnanta Pharmaceuticals3.8512 of 5 stars3.41.00.04.73.42.50.0EPRXEupraxia Pharmaceuticals2.106 of 5 stars3.71.00.00.02.50.00.6IGXTIntelGenx Technologies0.243 of 5 stars0.03.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00181.69% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25193.87% UpsideEPRXEupraxia Pharmaceuticals 3.33Buy$10.50171.32% UpsideIGXTIntelGenx Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IGXT, EPRX, ALEC, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/7/2025ALECAlectorMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight$3.00 ➝ $1.50(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$88.34M1.61N/AN/A$1.41 per share1.01ENTAEnanta Pharmaceuticals$64.46M1.95N/AN/A$5.24 per share1.12EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$130.39M-$1.26N/AN/AN/A-257.54%-108.77%-27.03%8/6/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$28.22M-$0.76N/AN/AN/AN/A-219.64%-96.00%8/6/2025 (Estimated)IGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/ALatest IGXT, EPRX, ALEC, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/A3/20/2025Q4 2024EPRXEupraxia Pharmaceuticals-$0.20-$0.21-$0.01-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlectorN/A3.293.29ENTAEnanta PharmaceuticalsN/A5.475.47EPRXEupraxia PharmaceuticalsN/A4.174.17IGXTIntelGenx TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ENTAEnanta Pharmaceuticals94.99%EPRXEupraxia PharmaceuticalsN/AIGXTIntelGenx TechnologiesN/AInsider OwnershipCompanyInsider OwnershipALECAlector9.10%ENTAEnanta Pharmaceuticals13.89%EPRXEupraxia PharmaceuticalsN/AIGXTIntelGenx Technologies42.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million89.02 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.37 millionOptionableEPRXEupraxia Pharmaceuticals2935.85 millionN/AN/AIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableIGXT, EPRX, ALEC, and ENTA HeadlinesRecent News About These CompaniesIntelgenx Technologies (OTC:IGXT) Stock Quotes, Forecast and News SummaryAugust 18, 2024 | benzinga.comIntelGenx Technologies Corp.: IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 20, 2024 | finanznachrichten.deIntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 19, 2024 | globenewswire.comIntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseJuly 3, 2024 | globenewswire.comIntelGenx Announces Initiation of the Sale and Investment Solicitation ProcessJune 11, 2024 | globenewswire.comIntelGenx Obtains Court-Approval of a Sale and Investment Solicitation ProcessMay 28, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 17, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 17, 2024 | globenewswire.comIntelGenx Announces Voting Results on Election of DirectorsMay 8, 2024 | globenewswire.comIntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical TrialApril 8, 2024 | finance.yahoo.comIntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical TrialApril 8, 2024 | globenewswire.comIntelGenx Updates Status of Buprenorphine Buccal Film ANDAApril 5, 2024 | globenewswire.comIntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | seekingalpha.comIntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | insidermonkey.comIGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023March 21, 2024 | investorplace.comIntelGenx Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 21, 2024 | globenewswire.comIGXT IntelGenx Technologies Corp.March 16, 2024 | seekingalpha.comIntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to FollowMarch 14, 2024 | globenewswire.comIntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life SciencesMarch 11, 2024 | globenewswire.comUPDATE -- IntelGenx Launches Preferred Share Regulation A OfferingFebruary 20, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGXT, EPRX, ALEC, and ENTA Company DescriptionsAlector NASDAQ:ALEC$1.42 +0.16 (+12.70%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.38 -0.03 (-2.46%) As of 05/28/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Enanta Pharmaceuticals NASDAQ:ENTA$5.87 +0.05 (+0.86%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$5.86 0.00 (-0.09%) As of 05/28/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Eupraxia Pharmaceuticals NASDAQ:EPRX$3.87 +0.01 (+0.26%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$3.88 +0.01 (+0.26%) As of 05/28/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
